Glaxo Said to Have Paid $1 Billion Over Paxil Suits

GlaxoSmithKline has agreed to pay more than $1 billion to resolve more than 800 cases alleging its Paxil antidepressant caused birth defects, according to sources familiar with the settlements.

The accords provide an average payout of more than $1.2 million to families of affected children, but still leave more than 100 birth-defect cases pending. Officials of Glaxo said they set aside $2.4 billion to resolve litigation over Paxil and the diabetes drug Avandia.

Bloomberg reports:

“The company had $11.7 billion in U.S. Paxil sales for nine years starting in 1997, according to documents made public last year in a Pennsylvania trial over birth-defect claims.”

+ Sources and References
Post your comment